Parkinson disease (PD) is the second most common neurodegenerative disorder, and, owing to the aging population, the number of patients with PD is expected to double by 2030.
1 Projected PD prevalence will be more than 1.6 million in the US with projected total economic burden surpassing $79 billion by 2037.
2 The diagnosis of PD is based on the clinical manifestations and findings from complex neuroimaging examinations, such as magnetic resonance imaging (MRI) or magnetic resonance angiography (MRA), which contribute to medical burden among patients with PD. Therefore, besides the established diagnostic method, many studies have been conducted to investigate the potential metrics for PD, translating these into clinically practical tools for the diagnosis and treatment of patients with PD.